SCHEMBL6170917

SCHEMBL6170917

COc1ccc(N(CC(=O)O)C(=O)C2CCS(=O)(=O)CC2)cc1

nearest known ligand 0.43

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
▸ KEAP1 Q14145 2/20 0.43
▸ NFE2L2 Q16236 2/20 0.43
▸ L3MBTL1 Q9Y468 1/20 0.43
▸ ALDH1A1 P00352 1/20 0.42
▸ LMNA P02545 1/20 0.42
▸ GAA P10253 1/20 0.42
▸ HTT P42858 1/20 0.40
▸ THRB P10828 1/20 0.39
▸ CHRM5 P08912 1/20 0.39
▸ CHRM1 P11229 1/20 0.39
▸ CHRM3 P20309 1/20 0.39
▸ MAPT P10636 1/20 0.39
▸ PTGIR P43119 2/20 0.39
▸ TSHR P16473 2/20 0.38
▸ ACHE P22303 1/20 0.38
▸ OPRM1 P35372 1/20 0.38
▸ PTGDR Q13258 1/20 0.38
▸ HSP90AA1 P07900 1/20 0.38
▸ SMN1; SMN2 Q16637 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2773909 0.86 CNR2 (0.45) KEAP1NFE2L2ALDH1A1GAAHTT
SCHEMBL6176749 0.85 CHRM5 (0.51) KEAP1NFE2L2GAACHRM5CHRM1
SCHEMBL6174617 0.85 HTT (0.46) KEAP1NFE2L2HTTCHRM3PTGIR
SCHEMBL6172831 0.84 KEAP1 (0.44) KEAP1NFE2L2HTTCHRM1CHRM3
SCHEMBL6171439 0.84 ALDH1A1 (0.50) KEAP1NFE2L2ALDH1A1HTTPTGIR
SCHEMBL6172035 0.81 KEAP1 (0.45) KEAP1NFE2L2HTTPTGIRTSHR
SCHEMBL6175650 0.76 STS (0.54) ALDH1A1HTT
SCHEMBL7106756 0.73 KEAP1 (0.55) KEAP1NFE2L2TSHRACHESMN1; SMN2
SCHEMBL4598838 0.73 GPR88 (0.48) ALDH1A1GAAHTTOPRM1HSP90AA1
SCHEMBL18930910 0.73 RNF4 (0.60) ALDH1A1LMNAHTTCHRM5CHRM1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6949543-B2 Amide derivative YAMANOUCHI PHARMACEUTICAL CO., LTD. (JP) 2005-09-27 — — US disclosed
EP-1340750-B1 AMIDE DERIVATIVES YAMANOUCHI PHARMA CO LTD (JP) 2005-08-17 — — EP disclosed
US-20040034232-A1 Amide derivative ASTELLAS PHARMA INC. (JP) 2004-02-19 — — US disclosed
EP-1340750-A1 AMIDE DERIVATIVES YAMANOUCHI PHARMACEUTICAL CO. LTD. (JP) 2003-09-03 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040034232-A1 Amide derivative HDAC2, ZC3HAV1, HDAC4 KEAP1 4651/4885NFE2L2 2014/4885L3MBTL1 1744/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback